BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38224916)

  • 21. Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial.
    Henke LE; Olsen JR; Contreras JA; Curcuru A; DeWees TA; Green OL; Michalski J; Mutic S; Roach MC; Bradley JD; Parikh PJ; Kashani R; Robinson CG
    Adv Radiat Oncol; 2019; 4(1):201-209. PubMed ID: 30706029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Silico Trial of Computed Tomography-Guided Stereotactic Adaptive Radiation Therapy (CT-STAR) for the Treatment of Abdominal Oligometastases.
    Schiff JP; Stowe HB; Price A; Laugeman E; Hatscher C; Hugo GD; Badiyan SN; Kim H; Robinson CG; Henke LE
    Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):1022-1031. PubMed ID: 35768023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases--clinical results.
    Boda-Heggemann J; Dinter D; Weiss C; Frauenfeld A; Siebenlist K; Attenberger U; Ottstadt M; Schneider F; Hofheinz RD; Wenz F; Lohr F
    Radiat Oncol; 2012 Jun; 7():92. PubMed ID: 22710033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simulated Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Disease of the Abdomen and Central Thorax: Characterization of Potential Advantages.
    Henke L; Kashani R; Yang D; Zhao T; Green O; Olsen L; Rodriguez V; Wooten HO; Li HH; Hu Y; Bradley J; Robinson C; Parikh P; Michalski J; Mutic S; Olsen JR
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1078-1086. PubMed ID: 27742541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Daily Plan Adaptation in MR-Guided Stereotactic Ablative Radiation Therapy for Adrenal Metastases.
    Palacios MA; Bohoudi O; Bruynzeel AME; van Sörsen de Koste JR; Cobussen P; Slotman BJ; Lagerwaard FJ; Senan S
    Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):426-433. PubMed ID: 29902559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.
    Palma DA; Olson R; Harrow S; Gaede S; Louie AV; Haasbeek C; Mulroy L; Lock M; Rodrigues GB; Yaremko BP; Schellenberg D; Ahmad B; Griffioen G; Senthi S; Swaminath A; Kopek N; Liu M; Moore K; Currie S; Bauman GS; Warner A; Senan S
    Lancet; 2019 May; 393(10185):2051-2058. PubMed ID: 30982687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of online adaptive MR-guided stereotactic body radiotherapy of liver cancers.
    Padgett KR; Simpson G; Asher D; Portelance L; Bossart E; Dogan N
    Phys Med; 2020 Sep; 77():54-63. PubMed ID: 32781388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
    König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J
    Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review.
    Gouveia AG; Chan DCW; Hoskin PJ; Marta GN; Trippa F; Maranzano E; Chow E; Silva MF
    Radiother Oncol; 2021 Oct; 163():55-67. PubMed ID: 34333087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
    Siva S; Bressel M; Murphy DG; Shaw M; Chander S; Violet J; Tai KH; Udovicich C; Lim A; Selbie L; Hofman MS; Kron T; Moon D; Goad J; Lawrentschuk N; Foroudi F
    Eur Urol; 2018 Oct; 74(4):455-462. PubMed ID: 30227924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
    Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
    Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of magnetic resonance-guided versus conventional radiotherapy workflows on organ at risk doses in stereotactic body radiotherapy for lymph node oligometastases.
    Werensteijn-Honingh AM; Kroon PS; Winkel D; van Gaal JC; Hes J; Snoeren LMW; Timmer JK; Mout CCP; Bol GH; Kotte AN; Eppinga WSC; Intven M; Raaymakers BW; Jürgenliemk-Schulz IM
    Phys Imaging Radiat Oncol; 2022 Jul; 23():66-73. PubMed ID: 35814260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A predictive model of polymetastatic disease from a multicenter large retrospectIve database on colorectal lung metastases treated with stereotactic ablative radiotherapy: The RED LaIT-SABR study.
    Nicosia L; Franceschini D; Perrone-Congedi F; Molinari A; Gerardi MA; Rigo M; Mazzola R; Perna M; Scotti V; Fodor A; Iurato A; Pasqualetti F; Gadducci G; Chiesa S; Niespolo RM; Bruni A; Cappelli A; D'Angelo E; Borghetti P; Di Marzo A; Ravasio A; De Bari B; Sepulcri M; Aiello D; Mortellaro G; Sangalli C; Franceschini M; Montesi G; Aquilanti FM; Lunardi G; Valdagni R; Fazio I; Scarzello G; Vavassori V; Maranzano E; Maria Magrini S; Arcangeli S; Gambacorta MA; Valentini V; Paiar F; Ramella S; Di Muzio NG; Loi M; Jereczek-Fossa BA; Casamassima F; Osti MF; Scorsetti M; Alongi F
    Clin Transl Radiat Oncol; 2023 Mar; 39():100568. PubMed ID: 36935855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of Quality of Life Decline in Patients with Oligometastases treated with Stereotactic Ablative Radiotherapy: Analysis of the Population-Based SABR-5 Phase II Trial.
    Cruz-Lim EM; Mou B; Jiang W; Liu M; Bergman A; Schellenberg D; Alexander A; Berrang T; Bang A; Chng N; Matthews Q; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson R; Baker S
    Clin Oncol (R Coll Radiol); 2024 Mar; 36(3):141-147. PubMed ID: 38296662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
    Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
    Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial.
    Olson R; Mathews L; Liu M; Schellenberg D; Mou B; Berrang T; Harrow S; Correa RJM; Bhat V; Pai H; Mohamed I; Miller S; Schneiders F; Laba J; Wilke D; Senthi S; Louie AV; Swaminath A; Chalmers A; Gaede S; Warner A; de Gruijl TD; Allan A; Palma DA
    BMC Cancer; 2020 May; 20(1):380. PubMed ID: 32370765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of Local Control for Stereotactic Ablative Radiotherapy (SAbR) in Pulmonary Oligometastases from Gastrointestinal Malignancies.
    Simoni N; Micera R; Rossi G; Giri MG; Pavarana M; Muraglia A; Cernusco NLV; DE Liguoro M; Guariglia S; Cavedon C; Milella M; Mazzarotto R
    Anticancer Res; 2020 Oct; 40(10):5901-5907. PubMed ID: 32988921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ablative radiation therapy to restrain everything safely treatable (ARREST): study protocol for a phase I trial treating polymetastatic cancer with stereotactic radiotherapy.
    Bauman GS; Corkum MT; Fakir H; Nguyen TK; Palma DA
    BMC Cancer; 2021 Apr; 21(1):405. PubMed ID: 33853550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiosurgery and fractionated stereotactic body radiotherapy for patients with lung oligometastases.
    Kalinauskaite GG; Tinhofer II; Kufeld MM; Kluge AA; Grün AA; Budach VV; Senger CC; Stromberger CC
    BMC Cancer; 2020 May; 20(1):404. PubMed ID: 32393261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.